Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma after Autologous Stem Cell Transplantation: Secondary Analysis from the Phase 3 Aspire Study (NCT01080391)

MLA

Hari, Parameswaran N., et al. “Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma after Autologous Stem Cell Transplantation: Secondary Analysis from the Phase 3 Aspire Study (NCT01080391).” Biology of Blood & Marrow Transplantation, vol. 22, Mar. 2016, pp. S66–67. EBSCOhost, https://doi.org/10.1016/j.bbmt.2015.11.1107.

APA

Hari, P. N., Song, K., Bensinger, W., Siegel, D., Davies, F., Huang, M., Iskander, K., Aggarwal, S., & Abonour, R. (2016). Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma after Autologous Stem Cell Transplantation: Secondary Analysis from the Phase 3 Aspire Study (NCT01080391). Biology of Blood & Marrow Transplantation, 22, S66–S67. https://doi.org/10.1016/j.bbmt.2015.11.1107

Chicago

Hari, Parameswaran N., Kevin Song, William Bensinger, David Siegel, Faith Davies, Mei Huang, Karim Iskander, Sanjay Aggarwal, and Rafat Abonour. 2016. “Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma after Autologous Stem Cell Transplantation: Secondary Analysis from the Phase 3 Aspire Study (NCT01080391).” Biology of Blood & Marrow Transplantation 22 (March): S66–67. doi:10.1016/j.bbmt.2015.11.1107.